Livzon Pharmaceutical Group Inc.

000513

CNE0000002Y8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-03 EDT			5-day change	1st Jan Change
39.81 ^CNY	+2.47%		+2.00%	+13.71%

05-27	Livzon Pharmaceutical Cancels 5.3 Million Share Options	MT
05-14	Livzon Pharmaceutical Group Cancels Share Options	MT

Livzon Pharmaceutical Group Inc. Elects Huang Jinhua as Independent Directors

July 01, 2020 at 03:33 pm

Livzon Pharmaceutical Group Inc. announced that at its Extraordinary General Meeting of 2020 on 30 June 2020, elected Huang Jinhua as independent directors.

Latest news about Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Cancels 5.3 Million Share Options	05-27	MT
Livzon Pharmaceutical Group Cancels Share Options	05-14	MT
Livzon Pharmaceutical Declares Final Dividend for 2023	05-13	MT
Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	04-26	CI
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	04-24	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.	04-02	CI
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	03-29	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	03-28	CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	02-23	MT
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	02-22	CI
Livzon Pharma Gets Nod to Trial Weight Management Drug	02-05	MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President	01-30	MT
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	01-18	CI
Livzon Pharma Recognizes Credit, Asset Impairments	01-10	MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical	01-02	MT
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics	12-18	MT
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List	12-14	MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	12-04	MT
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use	12-03	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 5% stake in Zhuhai Livzon Diagnostics Inc. from Shi Jianfeng.	11-20	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin.	11-20	CI
Livzon Pharma Boosts Stake in Diagnostic Equipment Unit Ahead of Spinoff	11-20	MT
Zhuhai Livzon Biomedical Technology Co., Ltd announced that it expects to receive CNY 1 billion in funding from Livzon Pharmaceutical Group Inc.	11-16	CI

Chart Livzon Pharmaceutical Group Inc.

Duration

Period

More charts

LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-06-14 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Livzon Pharmaceutical Group Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

39.81 CNY

Average target price

41.14 CNY

Spread / Average Target

+3.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIVZON PHARMACEUTICAL GROUP INC.	+13.71%	4.36B
ELI LILLY AND COMPANY	+42.83%	748B
NOVO NORDISK A/S	+34.11%	598B
JOHNSON & JOHNSON	-5.70%	356B
MERCK & CO., INC.	+18.06%	325B
ABBVIE INC.	+4.63%	283B
ASTRAZENECA PLC	+17.02%	245B
NOVARTIS AG	+9.26%	211B
ROCHE HOLDING AG	-4.21%	209B
PFIZER, INC.	+2.43%	166B

Other Pharmaceuticals